The geoepidemiology of the antiphospholipid antibody syndrome
M Biggioggero, PL Meroni - Autoimmunity reviews, 2010 - Elsevier
Antiphospholipid antibodies (aPL) can be detected by functional (lupus anticoagulant)
and/or by solid phase assays (anti-cardiolipin and anti-beta2 glycoprotein I). Although …
and/or by solid phase assays (anti-cardiolipin and anti-beta2 glycoprotein I). Although …
Sex and management of rheumatoid arthritis
EG Favalli, M Biggioggero, C Crotti, A Becciolini… - Clinical reviews in …, 2019 - Springer
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease more common
in women than men (3: 1). Although sex-based differences may play a complex role in …
in women than men (3: 1). Although sex-based differences may play a complex role in …
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
M Biggioggero, C Crotti, A Becciolini… - Drug design …, 2018 - Taylor & Francis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by articular and
systemic manifestations, such as anemia, fatigue, osteoporosis, and increased risk for …
systemic manifestations, such as anemia, fatigue, osteoporosis, and increased risk for …
[HTML][HTML] Baricitinib for COVID-19: a suitable treatment?
EG Favalli, M Biggioggero, G Maioli… - The Lancet Infectious …, 2020 - thelancet.com
3 Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019
(COVID19) from publicly reported confirmed cases: estimation and application. Ann Intern …
(COVID19) from publicly reported confirmed cases: estimation and application. Ann Intern …
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
MG Raimondo, M Biggioggero, C Crotti… - Drug Design …, 2017 - Taylor & Francis
In recent years the use of biotechnological agents has drastically revolutionized the
therapeutic approach and the progression of rheumatoid arthritis (RA). In particular …
therapeutic approach and the progression of rheumatoid arthritis (RA). In particular …
The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives
EG Favalli, MG Raimondo, A Becciolini, C Crotti… - Autoimmunity …, 2017 - Elsevier
The introduction of biologic disease–modifying anti-rheumatic drugs (bDMARDs) has
dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life …
dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life …
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug?
EG Favalli, M Biggioggero, PL Meroni - Autoimmunity reviews, 2014 - Elsevier
The improvement of rheumatoid arthritis (RA) management has been strictly related to
methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical …
methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical …
Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
EG Favalli, M Biggioggero, A Marchesoni… - …, 2014 - academic.oup.com
Objective. The aim of this study was to evaluate the survival on treatment with second-line
biologic therapy in RA patient non-responders to TNF inhibitors (TNFis) by comparing …
biologic therapy in RA patient non-responders to TNF inhibitors (TNFis) by comparing …
Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases
PL Meroni, M Biggioggero, SS Pierangeli… - Nature Reviews …, 2014 - nature.com
Autoantibody measurement is an excellent tool to confirm the diagnosis of rheumatic
autoimmune diseases. Hence, reliability and harmonization of autoantibody testing are …
autoimmune diseases. Hence, reliability and harmonization of autoantibody testing are …
Twelve‐year retention rate of first‐line tumor necrosis factor inhibitors in rheumatoid arthritis: real‐life data from a local registry
EG Favalli, F Pregnolato, M Biggioggero… - Arthritis care & …, 2016 - Wiley Online Library
Objective To evaluate the 12‐year survival of the first tumor necrosis factor inhibitor (TNFi)
treatment in a cohort of rheumatoid arthritis (RA) patients, comparing the between‐groups …
treatment in a cohort of rheumatoid arthritis (RA) patients, comparing the between‐groups …